Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients

What Was Tested

This randomized controlled trial paper looks at Amylin (Islet Amyloid Polypeptide) and CGRP (Calcitonin Gene-Related Peptide) in the context of migraine.

Migraine is a prevalent and disabling neurological disease.

Its genesis is poorly understood, and there remains unmet clinical need.

The researchers aimed to identify mechanisms and thus novel therapeutic targets for migraine using human models of migraine and translational models in animals, with emphasis on amylin, a close relative of calcitonin gene-related peptide (CGRP).

Who Took Part

Thirty-six migraine without aura patients were enrolled in a randomized, double-blind, 2-way, crossover, positive-controlled clinical trial study to receive infusion of an amylin analogue pramlintide or human αCGRP on 2 different experimental days.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Amylin (Islet Amyloid Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Amylin (Islet Amyloid Polypeptide).

Each person switched between Amylin (Islet Amyloid Polypeptide) and the comparison at some point, usually with a gap in between.

Furthermore, translational studies in cells and mouse models, and rat, mouse and human tissue samples were conducted.

What Was Measured

PubMed files the paper under topics including Amylin Receptor Agonists, Calcitonin Gene-Related Peptide, Islet Amyloid Polypeptide, Mice, Mice, Inbred C57BL, Migraine Disorders and Rats.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Amylin (Islet Amyloid Polypeptide) and CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Annals of neurology), a journal based in United States.

More context: the Amylin (Islet Amyloid Polypeptide) compound page and the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.